Stealth BioTherapeutics Corp is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. Stealth believes its lead product candidate, elamipretide, has the potential to treat both rare metabolic cardiomyopathies, such as Barth, Duchenne muscular dystrophy and Friedreich's ataxia, rare mitochondrial diseases entailing nuclear DNA mutations, such as POLG-related disorders, as well as ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration and Leber's hereditary optic neuropathy. Stealth is evaluating its second-generation clinical-stage candidate, SBT-272, and its new series of small molecules, SBT-550, for rare neurological disease indications following promising preclinical data. The Company has optimized its discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as scaffolds to deliver other compounds to mitochondria.
Company profile
Ticker
MITO
Exchange
Website
CEO
Irene P. McCarthy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
MITO stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
28 Nov 22
EFFECT
Notice of effectiveness
18 Nov 22
EFFECT
Notice of effectiveness
18 Nov 22
EFFECT
Notice of effectiveness
18 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 22
POS AM
Prospectus update (post-effective amendment)
16 Nov 22
POS AM
Prospectus update (post-effective amendment)
16 Nov 22
Latest ownership filings
SC 13D/A
Morningside Venture (I) Investments Ltd
23 Sep 22
SC 13D/A
Morningside Venture (I) Investments Ltd
1 Aug 22
SC 13D/A
Morningside Venture (I) Investments Ltd
27 Jun 22
SC 13D/A
Morningside Venture (I) Investments Ltd
10 Dec 21
SC 13D/A
Morningside Venture Investments Ltd
22 Nov 21
SC 13D/A
Morningside Venture (I) Investments Ltd
17 Feb 21
SC 13D/A
Morningside Venture (I) Investments Ltd
9 Nov 20
SC 13D/A
Morningside Venture (I) Investments Ltd
16 Apr 20
SC 13D/A
Stealth BioTherapeutics Corp
9 Jan 20
SC 13D/A
Stealth BioTherapeutics Corp
31 Dec 19
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2022
1.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 0 |
Closed positions | 7 |
Increased positions | 3 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 277.00 k |
Total shares | 895.90 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ikarian Capital | 435.52 k | $134.00 k |
Brown Brothers Harriman & Co | 175.00 k | $54.00 k |
Renaissance Technologies | 96.94 k | $30.00 k |
Geode Capital Management | 48.79 k | $15.00 k |
Boothbay Fund Management | 43.79 k | $14.00 k |
Susquehanna International | 30.99 k | $10.00 k |
Envestnet Asset Management | 23.25 k | $7.00 k |
Captrust Financial Advisors | 15.00 k | $5.00 k |
Two Sigma Advisers | 13.70 k | $4.00 k |
Advisor | 10.12 k | $3.00 k |